Press Releases

Year 2016

October 2016 - Astellas to Acquire Ganymed Pharmaceuticals

June 2016 - Ganymed's IMAB362 Extends Survival in Gastric Cancer

May 2016 - Ganymed to Present Exciting Phase II Clinical Data for IMAB362 in Gastroesophageal Cancer at ASCO 2016 Annual Meeting

Year 2014

October 2014 - BioNTech AG and Ganymed Pharmaceuticals AG Open New Research Headquarters in Mainz, Germany

Mainz, Germany, October 1, 2014 - BioNTech AG and Ganymed Pharmaceuticals AG, two premier German biotechology companies, announced today the joint- opening of a...

July 2014 - Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer

Mainz, Germany, July 22, 2014 - Ganymed Pharmaceuticals AG, a biopharmaceutical company developing Ideal Monoclonal Antibodies (IMABs) for the treatment of...

May 2014 - Ganymed’s IMAB362 Shows Strong Evidence of Single- Agent Activity in Phase IIa Trial in Gastroesophageal Cancer

Trial Results Demonstrate Safety and Therapeutic Benefits of Antibody

February 2014 - Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer

Second Antibody from Ganymed’s Ideal Monoclonal Antibody Platform in the Clinic

Year 2013

December 2013 - Ganymed Pharmaceuticals to present at the 32nd Annual J.P. Morgan Healthcare Conference

Ganymed Pharmaceuticals AG announced today that it will present at the 32nd Annual J.P. Morgan Healthcare Conference that will take place from January 13 to...

November 2013 - Ganymed Pharmaceuticals Closes EUR 45 Million Financing Round

Company to accelerate clinical development of antibodies IMAB362 and IMAB027 for the treatment of cancer

October 2013 - Ganymed’s IMAB362 Receives Orphan Drug Designation

Ganymed’s IMAB362 Receives Orphan Drug Designation From FDA & EMA for Pancreatic Cancer.

September 2013 - Ganymed Pharmaceuticals Announces CE Marking for Test to Assess Claudin-18.2 Expression in Solid Tumors

CLAUDETECT™ 18.2 is the first and only CE marked IVD test specific for the detection of Claudin-18.2 in gastroesophageal, pancreatic and other solid tumors

Year 2010

August 2010 - Clinical Phase I Results of GANYMED’s IMAB362

Clinical Phase I Results of GANYMED’s IMAB362 Antibody Demonstrate Excellent Safety

Year 2008 and earlier

November 2008 - GANYMED

GANYMED closes EUR 65 M Financing Round

August 2008 - ATS acquires majority shareholding in GANYMED

GANYMED Pharmaceuticals AG today announced the sale of a majority of the company shares to ATS.

August 2008 - Wie gründe ich ein Technologie-Unternehmen?

Tag der offenen Tür und Firmenbesichtigung im Biotechnikum mit dem Thema "Wie gründe ich ein Technologie-Unternehmen?

September 2007 - GANYMED

GANYMED increases Series C Financing in Second Closing to Euro 37.2 Million

April 2007 - GANYMED

GANYMED raises Euro 33.7 Million in Series C Financing Round

November 2006 - Neue Wege

Neue Wege gegen den Krebs gehen

November 2006 - Standort gesichert

Standort gesichert - Ganymed Pharmaceuticals AG bleibt in Mainz

October 2006 - Dr. Thomas M. Rinderknecht

Dr. Thomas M. Rinderknecht chairs Supervisory Board of GANYMED

April 2006 - GANYMED

GANYMED lead antibodies show excellent efficacy and safety in mouse tumor models

September 2005 - GANYMED

GANYMED scientists receive Georges-Köhler Award

August 2005 - GANYMED

GANYMED and the University of Mainz broaden their successful cooperation in the fight against cancer

July 2005 - GANYMED

GANYMED raises EUR 14.4 million in Series B Financing Round

June 2004 - GANYMED

GANYMED announces license of WT 1 Immunotherapy rights by CORIXA and KIRIN

April 2004 - Genmab

Genmab licenses cancer target from Ganymed

April 2004 - GANYMED

GANYMED names Rainer Wessel Ph.D. as President & CEO

March 2004 - New cooperation

New cooperation on Identification of Multiple Sclerosis Pathogens established between GANYMED Pharmaceuticals AG and the University of Rotterdam

December 2003 - GANYMED

GANYMED acquires ImmuGenics AG and In-licenses Technology from Imperial College London

November 2003 - GANYMED

GANYMED extended Research Collaboration with the Cantonal Hospital St. Gallen

November 2003 - GANYMED

GANYMED names James A. Ratigan CEO

November 2003 - GANYMED

GANYMED names 3 pharmaceutical industry executives to its Supervisory Board

June 2003 - Cooperation on Target

Cooperation on Target Validation established between GANYMED Pharmaceuticals AG and the University of Ghent

December 2002 - GANYMED

GANYMED Pharmaceuticals AG and Cantonal Hospital St. Gallen cooperate on Chlamydia pneumoniae research

June 2002 - GANYMED

GANYMED Pharmaceuticals AG secures 8.85 million EUR first-round financing